D2C7 IT
Alternative Names: D2C7; D2C7-Immunotoxin; D2C7-ITLatest Information Update: 17 Jun 2024
At a glance
- Originator Duke University Medical Center
- Developer Duke University Medical Center; Istari Oncology; National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors; Protein biosynthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioma
Most Recent Events
- 17 Jun 2024 Phase-I development is ongoing in USA (NCT06455605)
- 12 Jun 2024 Duke University in collaboration with Rockefeller University plans a phase I/II trial for Glioma (Combination therapy, Recurrent, Late-stage disease) in USA (Intratumoral, Infusion) in September 2024 (NCT06455605)
- 06 Sep 2023 Phase-I/II clinical trials in Glioma (Combination therapy, Late-stage disease, Newly diagnosed) in USA (Intratumoural) (NCT05734560)